Niacin status and treatment-related leukemogenesis

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 725-732

  Kirkland, James B ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ANTHRACYCLINE; DNA; DNA TOPOISOMERASE INHIBITOR; ETHYLNITROSOUREA; ETOPOSIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINIC ACID; NITROSOUREA; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RIBOFLAVIN; SIRTUIN; TAMOXIFEN; UBIDECARENONE; VITAMIN B GROUP; ANTINEOPLASTIC AGENT;

APOPTOSIS; BONE MARROW CELL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL SURVIVAL; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG DOSE COMPARISON; EXCISION REPAIR; GENOMIC INSTABILITY; HUMAN; IN VIVO STUDY; LEUKEMIA; LEUKEMOGENESIS; MICROCIRCULATION; NICOTINIC ACID DEFICIENCY; NONHUMAN; NUTRITION; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; SUPPLEMENTATION; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT; METABOLISM; NUTRITIONAL STATUS; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; HUMANS; LEUKEMIA; NIACIN; NUTRITIONAL STATUS; POLY ADENOSINE DIPHOSPHATE RIBOSE;

EID: 66449134807     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0042     Document Type: Short Survey

References (61)

1. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-1379, PubMed doi:10.1093/ jnci/djn310.
2. Lawless SC, Verma P, Green DM, Mahoney MC. Mortality experiences among 15+ year survivors of childhood and adolescent cancers. Pediatr Blood Cancer 2007;48:333-338, PubMed doi:10.1002/pbc.20723. (Pubitemid 46238526)
3. MacArthur AC, Spinelli JJ, Rogers PC, et al. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada. Pediatr Blood Cancer 2007;48:453-459, PubMed doi:10.1002/pbc.20921. (Pubitemid 46340113)
4. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues. Cancer 2009;115:23-35, PubMed doi:10.1002/cncr.23988.
5. Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol 2006;182:431-6, PubMed doi: 10.1007/s00066-006-1542-1548 (Pubitemid 44214485)
6. Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005;9 Suppl 2:S51-63, PubMed doi:10.1016/j.ejon.2005.09.007. (Pubitemid 41488128)
7. Smith DE, Stevens MC, Booth IW. Malnutrition at diagnosis of malignancy in childhood: common but mostly missed. Eur J Pediatr 1991;150: 318-322, PubMed doi:10.1007/BF01955930.
8. Koretz RL. Should patients with cancer be offered nutritional support: does the benefit outweigh the burden?. Eur J Gastroenterol Hepatol 2007; 19:379-382, PubMed doi:10.1097/MEG.0b013e3280bdc093. (Pubitemid 46596690)
9. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr 2001;131:616-33S, PubMed.
10. Kumpf VJ. Update on parenteraliron therapy. Nutr Clin Pract 2003; 18:318-326, PubMed doi:10.1177/0115426503018004318.
11. Hubner RA, Houlston RS. Folate and colorectal cancer prevention. Br J Cancer 2009;100:233-239, PubMed doi:10.1038/sj.bjc.6604823.
12. Inculet RI, Norton JA, Nichoalds GE, et al. Water-soluble vitamins in cancer patients on parenteralnutrition: a prospective study. JPEN J Parenter EnteralNutr 1987;11:243-249, doi:10.1177/0148607187011003243. (Pubitemid 17078039)
13. Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med 1990;87:163-7, 170. (Pubitemid 20041617)
14. Stevens HP, Ostlere LS, Begent RH, Dooley JS, Rustin MH. Pellagra secondary to 5-fluorouracil. Br J Dermatol 1993;128:578-580, PubMed doi:10.1111/j.1365-2133.1993.tb00240.x. (Pubitemid 23155960)
15. Kirkland JB. Niacin and carcinogenesis. Nutr Cancer 2003;46:110-118, PubMed doi:10.1207/S15327914NC4602-02.
16. Kirkland JB. Niacin. In: Rucker R, Zempleni J, Suttie JW, McCormick DB, editors. Handbook of vitamins. 4th ed. New York: Taylor and Francis; 2007, p. 191-232.
17. Kirkland JB, Zempleni J, Buckles LK, Christman JK. Vitamin-dependent modifications of chromatin: epigenetic events and genomic stability. In: Rucker RB, Zempleni J, Suttie JW, McCormick DB, editors. Handbook of vitamins. 4th ed. New York: Taylor and Francis; 2007, p. 521-544
18. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-528, PubMed doi:10.1038/nrm1963.
19. Gagne JP, Hendzel MJ, Droit A, Poirier GG. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin CellBiol20 06;18:145-151, PubMed doi:10.1016/j. ceb.2006.02.013. (Pubitemid 43375881)
20. Burkle A. DNA repair and PARP in aging. Free Radic Res 2006;40: 1295-1302, PubMed doi:10.1080/10715760600915288. (Pubitemid 44698279)
21. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functionalsynergy in mouse development. DNA Repair (Amst) 2004;3:1103-1108, PubMed doi:10.1016/j. dnarep.2004.06.002.
22. Menissier dM, Ricoul M, Tartier L, et al. Functionalintera ction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-2263
23. Sbodio JI, Lodish HF, Chi NW. Tankyrase-2 oligomerizes with tankyrase- 1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem J 2002;361:451-9, PubMed doi:10.1042/0264-6021:3610451. (Pubitemid 34177814)
24. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 2005;83:354-364, PubMed doi: 10.1139/o05-038. (Pubitemid 41297203)
25. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999; 342:249-68, PubMed doi:10.1042/0264-6021:3420249.
26. Kruszewski M, Szumiel I. Sirtuins (histone deacetylases III) in the cellular response to DNA damage-facts and hypotheses. DNA Repair (Amst) 2005;4:1306-1313, PubMed doi:10.1016/j.dnarep.2005.06.013.
27. Di Girolamo M, Dani N, Stilla A, Corda D. Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. FEBS J 2005;272:4565-4575, PubMed doi:10.1111/j.1742-4658.2005.04876.x. (Pubitemid 41366982)
28. Guse AH. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J 2005;272: 4590-4597, PubMed doi:10.1111/j.1742-4658.2005.04863.x. (Pubitemid 41366983)
29. Gerasimenko O, Gerasimenko J. New aspects of nuclear calcium signalling. J Cell Sci 2004;117:3087-3094, PubMed doi:10.1242/jcs.01295. (Pubitemid 39139896)
30. Boyonoski AC, Spronck JC, Gallacher LM, et al. Niacin deficiency decreases bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea- induced carcinogenesis in rats. J Nutr 2002;132:108-114, PubMed. (Pubitemid 34042463)
31. Boyonoski AC, Spronck JC, Jacobs RM, et al. Pharmacological intakes of niacin increase bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats. J Nutr 2002;132: 115-120, PubMed. (Pubitemid 34042464)
32. Tucker MA. Secondary cancers. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott Co.; 1993, p. 2407-2416
33. Shulman LN. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am 1993;7:325-335, PubMed. (Pubitemid 23115856)
34. Gerson SL, Trey JE, Miller K, Berger NA. Comparison of O6-alkylguanine- DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986;7:745-749, PubMed doi:10.1093/ carcin/7.5.745. (Pubitemid 17130635)
35. Shisa H, Hiai H. Genetically determined susceptibility of Fischer 344 rats to propylnitrosourea-induced thymic lymphomas. Cancer Res 1985; 45:1483-1487, PubMed. (Pubitemid 15079091)
36. Boyonoski AC, Gallacher LM, ApSimon MM, et al. Niacin deficiency in rats increases the severity of ethylnitrosourea-induced anemia and leukopenia. J Nutr 2000;130:1102-1107, PubMed. (Pubitemid 30233254)
37. Spronck JC, Bartleman AP, Boyonoski AC, Kirkland JB. Chronic DNA damage and niacin deficiency enhance cell injury and cause unusual interactions in NAD and poly(ADP-ribose) metabolism in rat bone marrow. Nutr Cancer 2003;45:124-131, PubMed doi:10.1207/S15327914NC4501-14. (Pubitemid 36736899)
38. Bartleman AP, Jacobs R, Kirkland JB. Niacin supplementation decreases the incidence of alkylation-induced nonlymphocytic leukemia in Long-Evans rats. Nutr Cancer 2008;60:251-258, PubMed doi: 10.1080/01635580701649628.
39. Seeberg E, Eide L, Bjoras M. The base excision repair pathway. Trends Biochem Sci 1995;20:391-7, PubMed doi:10.1016/S0968-0004(00) 89086-89096
40. Satoh MS, Poirier GG, Lindahl T. NAD(+)-dependent repair of damaged DNA by human cell extracts. J Biol Chem 1993;268:5480-5487, PubMed. (Pubitemid 23090866)
41. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980;283:593-596, PubMed doi: 10.1038/283593a0.
42. Kostecki LM, Thomas M, Linford G, et al. Niacin deficiency delays DNA excision repair and increases spontaneous and nitrosourea-induced chromosomalinst ability in rat bone marrow. Mutat Res 2007;625:50-61, PubMed. (Pubitemid 350016105)
43. Cox MM, Goodman MF, Kreuzer KN, et al. The importance of repairing stalled replication forks. Nature 2000;404:37-41, PubMed doi: 10.1038/35003501. (Pubitemid 30143124)
44. Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004;23:3872-3882, PubMed doi:10.1038/sj.onc.1207491. (Pubitemid 38725700)
45. Spronck JC, Nickerson JL, Kirkland JB. Niacin deficiency alters p53 expression and impairs etoposide-induced cell cycle arrest and apoptosis in rat bone marrow cells. Nutr Cancer 2007;57:88-99, PubMed. (Pubitemid 46871573)
46. Frosina G, Fortini P, Rossi O, et al. Two pathways for base excision repair in mammalian cells. J Biol Chem 1996;271:9573-9578, PubMed doi: 10.1074/jbc.271.16.9573. (Pubitemid 26137362)
47. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004;279:55117-55126, PubMed doi:10.1074/jbc.M404524200. (Pubitemid 40066505)
48. Spronck JC, Kirkland JB. Niacin deficiency increases spontaneous and etoposide-induced chromosomal instability in rat bone marrow cells in vivo. Mutat Res 2002;508:83-97, PubMed. (Pubitemid 34042463)
49. Won J, Chung SY, Kim SB, et al. Dose-dependent UV stabilization of p53 in cultured human cells undergoing apoptosis is mediated by poly (ADP-ribosyl)ation. Mol Cells 2006;21:218-223, PubMed.
50. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002;21: 2383-2396, PubMed doi:10.1093/emboj/21.10.2383. (Pubitemid 34546711)
51. Cohausz O, Blenn C, Malanga M, Althaus FR. The roles of poly(ADPribose)- metabolizing enzymes in alkylation-induced cell death. Cell Mol Life Sci 2008;65:644-55, PubMed doi:10.1007/s00018-008-7516-7525
52. Premkumar VG, Yuvaraj S, Shanthi P, Sachdanandam P. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy. Br J Nutr 2008;100:1179-1182, PubMed doi:10.1017/ S0007114508968276.
53. Agote M, Viaggi M, Kreimann E, et al. Influence of nicotinamide on the radiosensitivity of normaland goitrous thyroid in the rat. Thyroid 2001;11: 1003-1007, PubMed doi:10.1089/105072501753271671. (Pubitemid 33107911)
54. Ruddock MW, Burns DM, McKeown SR, et al. Contractile properties of human renalcel lcarcinoma recruited arteries and their response to nicotinamide. Radiother Oncol2000;54:179 -84, PubMed doi:10.1016/ S0167-8140(99)00163-172
55. Ruddock MW, Hirst DG. Nicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: implications for anticancer efficacy. Oncol Res 2004;14:483-489, PubMed. (Pubitemid 39551561)
56. Rojas A, Stratford MR, Bentzen SM, Denekamp J. Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?. Int J Radiat Biol2004 ;80:499-506, PubMed doi:10.1080/ 09553000410001724199. (Pubitemid 39037106)
57. Hoskin P, Rojas A, Saunders M. Accelerated radiotherapy, carbogen, and nNicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys;Epub 2008 Nov 24.
58. Gupta N, Saleem A, Kotz B, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 2006;12: 3115-23, PubMed doi:10.1158/1078-0432.CCR-05-0513. (Pubitemid 43837359)
59. Ratnam K, Low JA. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8, PubMed doi:10.1158/1078-0432.CCR-06-2260. (Pubitemid 46450426)
60. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008;1138:136-145 PubMed.
61. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channelaxis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51, PubMed doi:10.1016/j.ccr. 2006.10.020. (Pubitemid 46054520)